Clinical trials: Primary Hypertension
Hypertension
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.
- Trial name
- NCT00696241
- Testing
- Azilsartan medoxomil and olmesartan, Olmesartan
- Where
- 85 sites in United States, Argentina and 1 more
- Volunteers
- 1,275 people
- Sponsor
- Takeda
Primary Open Angle Glaucoma (POAG)
Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy
The purpose of this study is to evaluate the safety and effectiveness of CyPass implantation as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at…
- Trial name
- DUETTE (NCT01166659)
- Testing
- CyPass Micro-Stent
- Volunteers
- 48 people
- Sponsor
- Transcend Medical, Inc.
Glaucoma and Ocular Hypertension
Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02371746
- Testing
- ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
- Where
- 14 sites in United States
- Volunteers
- 41 people
- Sponsor
- Envisia Therapeutics
Essential Hypertension
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
This study will assess whether LCZ696 when used in combination with amlodipine will provide greater BP lowering benefit compared to amlodipine alone in Asian hypertensive patients not adequately responsive to amlodipine therapy.
- Trial name
- NCT01663233
- Testing
- LCZ696, Amlodipine
- Where
- 28 sites in China, Japan and 4 more
- Volunteers
- 266 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Vascular Diseases
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE-II (NCT03614260)
- Testing
- Paradise Renal Denervation System, Renal Angiogram
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- ReCor Medical, Inc.
Hypertension, Hypertension in Pregnancy
Bridging the Gap From Postpartum to Primary Care
Chronic health conditions affect most older adults. Preventative medicine and risk management strategies, especially when applied earlier in life, are essential to altering the trajectory of a disease and ultimately improving…
- Conditions
- Hypertension, Hypertension in Pregnancy, Diabetes Mellitus, Gestational Diabetes
- Trial name
- NCT05543265
- Testing
- Default appointment scheduling, Targeted messaging, Nudge Reminders
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Massachusetts General Hospital
Pulmonary Artery Hypertension
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.
- Trial name
- NCT04456998
- Testing
- GB002 (seralutinib), Generic Dry Powder Inhaler
- Where
- 63 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular…
- Trial name
- NCT01735214
- Testing
- Prostaglandin Analogue -Containing IOP-Lowering Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 358 people
- Sponsor
- Allergan
Essential Hypertension
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies…
- Trial name
- NCT03514641
- Testing
- Bexagliflozin
- Where
- 87 sites in United States
- Volunteers
- 673 people
- Sponsor
- Theracos
Ocular Hypertension, Glaucoma
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or…
- Trial name
- NCT00809848
- Testing
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Allergan
Pulmonary Artery Hypertension
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health…
- Trial name
- NCT03617458
- Testing
- Metformin, mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Vanderbilt University Medical Center
Primary Open-angle Glaucoma
Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)
The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-IO system in patients with Primary Open Angle Glaucoma (POAG)
- Trial name
- NCT03651336
- Testing
- ARGOS-IO Sensor Pressure System
- Where
- 4 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Glaucoma
Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
The study aims to further understand glaucoma pathogenesis and progression by utilizing enhanced depth imaging optical coherence tomography to visualize and measure lamina cribrosa in vivo and segmentation technology to…
- Trial name
- NCT02622191
- Testing
- Spectral domain Optical Coherence Tomography
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Wills Eye
Hypertension
PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular…
- Trial name
- NCT00936208
- Where
- 120 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 3,184 people
- Sponsor
- Boehringer Ingelheim
Glaucoma, Open-Angle, Ocular Hypertension
Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
Phase IV randomized, double blind, multicenter, parallel group clinical study to evaluate the efficacy of the combined use of Krytantek Ofteno PF® and Gaap Ofteno PF®, both applied every 12 hours, versus the use of Eliptic Ofteno…
- Trial name
- PRO-122 (NCT04702789)
- Testing
- Dorzolamide-timolol-brimonidine and latanoprost, Dorzolamide-timolol and latanoprost
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Essential Hypertension
Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension
This study is to determine the change in blood pressure from the administration of Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations with Olmesartan/Amlodipine.
- Trial name
- NCT00923091
- Testing
- olmesartan medoxomil + amlodipine + hydroclororthiazide, olmesartan medoxomil + amlodipine
- Where
- 133 sites in Belgium, Bulgaria and 13 more
- Volunteers
- 2,689 people
- Sponsor
- Daiichi Sankyo
Hypertension, Pulmonary Arterial Hypertension
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH).
- Conditions
- Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension
- Trial name
- T3PAH (NCT03528902)
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt University Medical Center
Hypertension
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg
Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/amlodipine combination based…
- Trial name
- EXPLOR (NCT00687973)
- Testing
- Valsartan/amlodipine 80/5 mg tablets, Amlodipine 5 mg capsules, Amlodipine 10 mg capsules
- Where
- France
- Volunteers
- 393 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Left Ventricular Hypertrophy
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.
- Conditions
- Hypertension, Left Ventricular Hypertrophy, Overweight
- Trial name
- ALLAY (NCT00219141)
- Testing
- Aliskiren 150/300 mg, Losartan 50/100 mg
- Where
- 9 sites in United States, Argentina and 7 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.